Table 3.
RFS and pCR rates for 42 patients classified by clinical and genetic characteristics
| |
Response to neoadjuvant chemotherapy |
Relapse-free survival |
|||||
|---|---|---|---|---|---|---|---|
| pCR | No pCR | P-value | No. of Patients (No. of events) | 3-year estimates | 95% CI | P-value | |
| All patients |
20 |
17 |
|
42 (12) |
0.72 |
0.55-0.89 |
|
| Response to neoadjuvant chemotherapy |
|
|
|
|
|
|
|
| pCR (grade 3) |
|
|
|
20 (4) |
0.73 |
0.52-0.93 |
0.764 |
| No pCR (grade 0~2) |
|
|
|
17 (5) |
0.86 |
0.67-1.04 |
|
| Hormone receptors |
|
|
|
|
|
|
|
| Positive |
8 |
14 |
0.009 |
25 (7) |
0.76 |
0.58-0.95 |
0.914 |
| Negative |
12 |
3 |
|
17 (5) |
0.69 |
0.42-0.95 |
|
|
HER2 copy numbers |
|
|
|
|
|
|
|
| ≤ 2.0 |
1 |
6 |
0.019 |
8 (5) |
0.57 |
0.20-0.94 |
0.095 |
| > 2.0 |
19 |
11 |
|
34 (7) |
0.78 |
0.62-0.94 |
|
| Wild-type HER2 mRNA |
|
|
|
|
|
|
|
| < 400 |
8 |
9 |
0.208 |
20 (8) |
0.61 |
0.40-0.83 |
0.022 |
| ≥ 400 |
11 |
5 |
|
17 (2) |
0.92 |
0.76-1.07 |
|
| ∆16HER2 mRNA |
|
|
|
|
|
|
|
| < 4.5 |
5 |
8 |
0.020 |
17 (5) |
0.72 |
0.50-0.93 |
0.314 |
| ≥ 4.5 |
15 |
4 |
|
20 (5) |
0.75 |
0.53-0.96 |
|
| Percentages of ∆16HER2 mRNA |
|
|
|
|
|
|
|
| < 2.4% |
17 |
11 |
0.581 |
31 (6) |
0.79 |
0.63-0.94 |
0.039 |
| ≥ 2.4% |
5 |
1 |
|
6 (4) |
0.50 |
0.10-0.90 |
|
|
PIK3CA |
|
|
|
|
|
|
|
| Wild-type |
18 |
14 |
0.498 |
36 (9) |
0.79 |
0.64-0.94 |
0.171 |
| Mutated |
2 |
3 |
|
6 (3) |
0.42 |
−0.02-0.85 |
|
|
PIK3CA |
|
|
|
|
|
|
|
| Wild-type + Normal + Loss + UPD |
16 |
9 |
0.08 |
28 (6) |
0.85 |
0.70-1.01 |
0.041 |
| Mutated + Gain |
4 |
8 |
|
14 (6) |
0.56 |
0.29-0.83 |
|
|
PTEN |
|
|
|
|
|
|
|
| Normal + Gain + UPD |
20 |
12 |
0.009 |
37 (11) |
0.73 |
0.56-0.89 |
0.705 |
| Loss |
0 |
5 |
|
5 (1) |
0.80 |
0.45-1.15 |
|
|
INPP4B |
|
|
|
|
|
|
|
| Normal + Gain + UPD |
17 |
16 |
0.373 |
36 (8) |
0.79 |
0.64-0.94 |
0.095 |
| Loss |
3 |
1 |
|
6 (4) |
0.50 |
0.10-0.90 |
|
|
PI3KCA , PTEN, INPP4B |
|
|
|
|
|
|
|
| No aberrations* |
14 |
6 |
0.086 |
22 (4) |
0.81 |
0.60-1.01 |
0.195 |
| Aberrations** |
6 |
11 |
|
20 (8) |
0.67 |
0.45-0.89 |
|
|
DEK |
|
|
|
|
|
|
|
| Normal |
13 |
14 |
0.236 |
28 (5) |
0.88 |
0.75-1.01 |
0.006 |
| Gain |
7 |
3 |
|
14 (7) |
0.44 |
0.14-0.75 |
|
|
FGFR1 |
|
|
|
|
|
|
|
| Normal + Loss + UPD |
17 |
9 |
0.035 |
29 (9) |
0.75 |
0.48-0.86 |
0.641 |
| Gain |
3 |
8 |
|
13 (3) |
0.92 |
0.76-1.07 |
|
|
CCND1 |
|
|
|
|
|
|
|
| Normal + Loss |
11 |
12 |
0.33 |
25 (4) |
0.84 |
0.68-1.01 |
0.043 |
| Gain |
9 |
5 |
|
17 (8) |
0.58 |
0.33-0.84 |
|
|
FOXA1 |
|
|
|
|
|
|
|
| Normal + UPD |
15 |
13 |
0.917 |
30 (6) |
0.80 |
0.64-0.96 |
0.012 |
| Gain |
5 |
4 |
|
12 (6) |
0.60 |
0.29-0.91 |
|
|
CDH3 |
|
|
|
|
|
|
|
| Normal + Loss + UPD |
19 |
14 |
0.217 |
37 (8) |
0.79 |
0.64-0.94 |
0.009 |
| Gain |
1 |
3 |
|
5 (4) |
0.40 |
−0.03-0.83 |
|
|
BIRC5 |
|
|
|
|
|
|
|
| Normal + Loss + UPD |
14 |
13 |
0.659 |
27 (5) |
0.82 |
0.66-0.98 |
0.005 |
| Gain |
6 |
4 |
|
15 (7) |
0.56 |
0.25-0.88 |
|
|
MYBL2 |
|
|
|
|
|
|
|
| Normal + Loss |
18 |
10 |
0.028 |
30 (7) |
0.80 |
0.64-0.96 |
0.053 |
| Gain |
2 |
7 |
|
12 (5) |
0.58 |
0.24-0.91 |
|
|
AIB1 |
|
|
|
|
|
|
|
| Normal + Loss |
18 |
11 |
0.063 |
31 (7) |
0.81 |
0.65-0.96 |
0.017 |
| Gain | 2 | 6 | 11 (5) | 0.52 | 0.15-0.89 | ||
CI, confidence interval; *No aberrations, wild-type and a normal copy of PIK3CA, a normal copy, gain or UPD of PTEN or INPP4B; **Aberrations, mutated and/or gain of PIK3CA, and loss of PTEN or INPP4B.